Key facts
- Adhere+’s last known valuation is $79.0M (Dec 2024).
- It has raised $2.5M; the latest was PE Growth/Expansion ($50K) in Mar 2026.
- Notable investors include JStar Capital.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Adhere+
- ·The full record, as it builds
Funding rounds
No funding rounds for Adhere+ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adhere+
Operator of a clinical data analytics firm (C-DAC) intended to empower healthcare providers with actionable real-world evidence (RWE). The company's clinically validated platform offers real-time doctor-patient interactions, automates daily check-ins, and real-time triage, facilitates actionable reporting, and simplifies care delivery while providing early warnings to catch potential health issues between visits, enabling clients to timely intervene, improve care quality, and reduced administrative burden while improving patients experience through proactive medication adherence and outcomes.
- Sector
- Healthcare
- HQ
- Washington, DC, United States
- Founded
- 2017
- Employees
- 11
- Website
- adhereplus.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Adhere+ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adhere+ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adhere+ in its N-PORT filings yet. We sweep new filings monthly.